Novartis signs license agreement for cancer-compound from

Novartis signs license agreement to develop and globally commercialize cancer-compound Gimatecan from Sigma-Tau

Oral Topoisomerase I inhibitor in Phase II development expands Novartis' leading Oncology pipeline

Basel, 6 November 2003 - Novartis Pharma AG has signed an agreement with Sigma-Tau of Rome, Italy, for the rights to develop and commercialize Gimatecan, a next generation oral topoisomerase I inhibitor in Phase II development for the treatment of common solid tumors.

Please see full press release under the following link:

Recommended Reading

September 18, 2026 10:51 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based...
Read More
September 08, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Read More

Novartis signs license agreement for cancer-compound from Sigma-Tau

Attachments

Recommended Reading